Clinical trial · Interventional
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study compares overall survival between patients with acute myeloid leukemia, who are in complete remission following initial treatment with chemotherapy and whose remission is maintained either with a transplantation of stem cells obtained from a sibling or unrelated donor or with standard treatment, which is additional chemotherapy. The study hypothesis is that the group transplanted with stem cells from a donor will have a superior survival compared with patients treated with standard of care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Reduced Intensity Conditioning Stem Cell Transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Stem cell transplant (RICT)
- description
- Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
- interventionNames
- Procedure: Reduced Intensity Conditioning Stem Cell Transplantation
- type
- NO_INTERVENTION
- label
- Control arm
- description
- Treatment according to standard of care, i.e. not undergoing RICT
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- From Inclusion until one of the above events (≥2yrs in all surviving pts).
- description
- OS is the time from Inclusion to death, lost to follow-up, refusal, or study termination.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 51 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed patients with de novo or secondary AML * Intermediate or poor risk * In first complete remission * Age 51-70 years * Fit for the procedure * Fit for further consolidation chemotherapy Exclusion Criteria: * Planned for a full-dose allogeneic transplant
References
Publications (0)
Data not yet available